Early Detection and Screening of Hematological Malignancies - SANGUINE

Prior treatment

• Patients/subjects with active inflammatory autoimmune disease that requires treatment with immunosuppressive/ immunomodulation agents;

Other illness

• Patients/subjects with current co-diagnosis of another type of cancer;
• Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection;
• Patients/subjects with known human immunodeficiency virus (HIV) positive;
• Patients/subjects with known active Hepatitis A/B/C or past hepatitis C;

Other

• Patients with a diagnosis of acute promyelocytic leukemia (APL)
• Subjects that are likely to be noncompliant with the protocol, or felt to be unsuitable by the investigator for any other reason.

• General criteria for all study populations:
• Male and female subjects ≥18 years of age
• Ability to understand and willingness to sign a written informed consent document.
  • For Patients with hematological malignancies:
  • 1\. Patients who have been diagnosed, have measurable disease, and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS that did not yet undergo any treatment.
  • NOTE:
  • Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, who were treated for their primary disease (FL/MZL/MDS/MPN) before study enrollment, are eligible.
  • For subjects at risk for developing the investigated hematological malignancies:
• First-degree relatives; AND /OR
• Elderly subjects ≥ 65 years of age.